Abstract
The incidence of gestational diabetes mellitus (GDM) is increasing. GDM is associated with adverse pregnancy outcomes and has long-term implications for both mother and child. The management of GDM is still controversial. As insulin therapy is effective and safe, it is considered as the first choice of pharmacotherapy for GDM. Recent studies have shown that the short acting insulin analogs such as lispro and aspart, and oral anti-diabetic agents such as glyburide and metformin, are safe, but there are only limited data to support the use of long acting insulin analogs. Key words: Gestational diabetes mellitus; Insulin analogs; Oral anti-diabetic agents
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
